British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma
The UK gastroenterology society's 2023 guideline for bile duct cancer, written with patient charities; there is no equivalent UK guideline written for gallbladder cancer.
Overview
Guideline commissioned by the British Society of Gastroenterology liver section, written by a multidisciplinary committee with patient and public representatives from AMMF (the Cholangiocarcinoma Charity) and PSC Support, with evidence graded in the AGREE II format. The recommendations are framed as guidance rather than protocol. Its scope is cholangiocarcinoma; a Europe PMC search on 24 September 2026 found no UK society guideline specific to gallbladder cancer, so UK gallbladder practice draws on this document, the ESMO guideline and NCCN.
- Multidisciplinary UK guideline for cholangiocarcinoma with patient representation and AGREE II grading; gallbladder cancer is outside its stated scope.
For a UK patient with gallbladder cancer the nearest national guideline is about a neighbouring disease; the UK and NHS page for gallbladder cancer names the gap.
- Scope is cholangiocarcinoma, not gallbladder cancer.
- Guidance rather than protocol, by the authors' own framing.
Similar pages
not linked directly; found by shared links- Key paperSecond-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Shares Juan W. Valle, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperDurvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
Shares Juan W. Valle, Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperClinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperBiliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperHER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Shares Juan W. Valle, Gallbladder cancer and the tag gallbladder-evidence.
- Key paperNeoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperLiposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Shares Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer and the tag gallbladder-evidence.
- Key paperIncidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis
Shares Gallbladder cancer and the tag gallbladder-evidence.